Agilent Announces New SureSelet Human All Exon V8


Agilent Technologies Inc. (NYSE: A) today announced the release of Sure Select Human All Exon V8  – a new exome design that provides comprehensive content and up-to-date coverage of protein-coding regions from RefSeq, CCDS, and GENCODE. It also covers the TERT promoter and hard-to-capture exons that are omitted by other exomes on the market. The new design is available in three options – routine exome sequencing (Exome v8), clinical research sequencing (v8 Clinical Plus), and translational research (v8 UTR Plus) – allowing for content flexibility to meet our customer’s needs.

Read more about this news here.

Related articles

Recent articles